DDInter740 DDInter1594
Flecainide is a Class I anti-arrhythmic agent like [encainide] and [propafenone]. Flecainide’s development began in 1966 and was first synthesized in 1972 as an attempt to generate new anesthetics. It is used to prevent supraventricular and ventricular arrhythmias, as well as paroxysmal atrial fibrillation and flutter.[L8878,L5056] Flecainide was granted FDA approval on 31 October 1985.
Rilonacept is a dimeric fusion protein consisting of portions of IL-1R and the IL-1R accessory protein linked to the Fc portion of immunoglobulin G1. Rilonacept functions as an interleukin 1 inhibitor and is used in the treatment of CAPS, also known as cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome (FCAS) and Muckle-Wells Syndrome (MWS), in adults and children greater than 12 years old.
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Romidepsin
Romidepsin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Procainamide
Procainamide {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rucaparib
Rucaparib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Osimertinib
Osimertinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Flecainide {u} (Compound) resembles {v} (Compound) Mefloquine
Mefloquine {u} may lead to a major life threatening interaction when taken with {v} Nilotinib
Nilotinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is upregulated by {v} (Compound) Nifedipine
Nifedipine {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Flecainide {u} (Compound) upregulates {v} (Gene) MTHFD2
MTHFD2 {u} (Gene) is downregulated by {v} (Compound) Dactinomycin
Dactinomycin {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Flecainide {u} (Compound) upregulates {v} (Gene) HMOX1
HMOX1 {u} (Gene) is bound by {v} (Compound) Vitamin E
Vitamin E {u} may cause a minor interaction that can limit clinical effects when taken with {v} Rilonacept
Flecainide {u} (Compound) upregulates {v} (Gene) AARS
AARS {u} (Gene) is upregulated by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Flecainide {u} (Compound) binds {v} (Gene) CYP2D6
CYP2D6 {u} (Gene) is bound by {v} (Compound) Ponatinib
Ponatinib {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Rilonacept
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Romidepsin and Romidepsin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Procainamide (Compound) and Procainamide may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may cause a moderate interaction that could exacerbate diseases when taken with Rucaparib and Rucaparib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may lead to a major life threatening interaction when taken with Osimertinib and Osimertinib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Flecainide (Compound) resembles Mefloquine (Compound) and Mefloquine may lead to a major life threatening interaction when taken with Nilotinib and Nilotinib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is upregulated by Nifedipine (Compound) and Nifedipine may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Flecainide (Compound) upregulates MTHFD2 (Gene) and MTHFD2 (Gene) is downregulated by Dactinomycin (Compound) and Dactinomycin may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Flecainide (Compound) upregulates HMOX1 (Gene) and HMOX1 (Gene) is bound by Vitamin E (Compound) and Vitamin E may cause a minor interaction that can limit clinical effects when taken with Rilonacept
Flecainide (Compound) upregulates AARS (Gene) and AARS (Gene) is upregulated by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept
Flecainide (Compound) binds CYP2D6 (Gene) and CYP2D6 (Gene) is bound by Ponatinib (Compound) and Ponatinib may cause a moderate interaction that could exacerbate diseases when taken with Rilonacept